Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in ...

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

Recursion Pharmaceuticals (RXRX), Crispr Therapeutics (CRSP), iShares MSCI India (INDA), Faraday Future Intelligent Electric (FFIE), Bilibili (BILI), Procter & Gamble (PG), UP Fintech Holding Ltd ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the target of some unusual options trading on Thursday. Investors acquired 23,699 call options on the company. This is an increase ...

Short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) decreased during the last ... on the decline of Recursion Pharmaceuticals's stock. Short interest data is updated every two weeks.